La cadena de opciones muestra datos clave de las opciones de acciones de Jasper Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Jasper Therapeutics..

Jasper Therapeutics (NASDAQ:JSPR) Bolsa, Cadena de Opciones

Jasper Therapeutics

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics Inc

News

Management

IMVT

Immunovant Appoints Eric Venker (Currently President And COO Of Roivant) As CEO, Tiago Girao As CFO, Following Pete Salzmann's Retirement as CEO and Director

Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) with a Buy and maintains $28 price target.

Price Target

Reiteration

Analyst Ratings

PHAT

Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target

Barclays analyst Adrienne Yih initiates coverage on Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) with a Equal-Weight rating and announces Price Target of $71.

Initiation

Barclays Initiates Coverage On Abercrombie & Fitch with Equal-Weight Rating, Announces Price Target of $71

Benchmark analyst David Williams maintains Belden (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDC#NYSE">BDC</a>) with a Buy and lowers the price target from $130 to $120.

Benchmark Maintains Buy on Belden, Lowers Price Target to $120

Net interest income is expected to be up slightly in 2Q25, relative to 1Q25, due to a stable NIM and an increased day count despite lower projected average and end of period loan balances. nDeposit balances are expected to be flat in 2Q25, relative to 1Q25. nWith current liquidity levels, we may increase debt security purchases during the remainder of 2025, if yields are attractive. nNoninterest income is expected to increase slightly during 2Q25, relative to 1Q25. nNoninterest expense expected to be between $31 million and $33 million per quarter in 2025. nAsset quality expected to remain solid, although a return to more normalized asset quality metrics and charge-offs may occur should the economy soften. Additionally, there may be more volatility in the CECL calculation if we see large movements in forecast unemployment and GDP. nStock repurchase program will continue to be used opportunistically with $15 million available through January 1, 2026. nCurrent capital levels and operational structure support M&amp;A should the right opportunity arise.

Guidance

HBT Projects Stable Net Interest Income and Modest Growth in Noninterest Income for 2Q25

JP Morgan analyst Richard Choe initiates coverage on Dycom Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DY#NYSE">DY</a>) with a Overweight rating and announces Price Target of $200.

JP Morgan Initiates Coverage On Dycom Industries with Overweight Rating, Announces Price Target of $200

As Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) trades within a narrow range, analysts urge traders to pivot away from momentum-driven strategies and adopt professional-grade trading techniques to profit in <a href="https://www.benzinga.com/money/bitcoin-price-prediction">a low-volatility environment</a>.
What Happened: A 10x Research report on Monday outlined how Bitcoin's sharp rallies in 2024 were limited to just two months, February (+44%) and November (+37%), while the rest of the year was characterized by consolidation.
Despite Bitcoin's strong annual return of +113%, the report emphasizes that most of the gains were compressed into brief windows, and that the current trading environment requires more tactical positioning.
"Bitcoin tends to perform better between October and March and consolidate between April and September," the analysts stated. "It makes sense to adopt a more conservative, seasonally aware approach during this part of the year."
The firm notes that retail participation has sharply declined in 2025, as evidenced by falling volumes during weekends and holidays, a shift that underscores the growing influence of institutional players.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44879425/bitcoin-to-outperform-gold-in-coming-months-says-anthony-pompliano">Bitcoin To Outperform Gold In Coming Months, Says Anthony Pompliano</a>
Why It Matters: Meanwhile, technical signals and on-chain metrics suggest caution.
The report identifies $73,000 as a likely downside limit but emphasizes the lack of strong upward catalysts in the near term.
Given this market backdrop, 10x Research suggests traders focus on structured strategies to generate yield or hedge risk. 
Among these, selling options in a range-bound market is seen as a particularly viable approach.
"With implied volatility dropping from 73% to 37% ahead of and following the April 6 decline, traders who sold puts were able to profit both from the fade in downside and from the volatility collapse," the report noted. 
This dual advantage, according to the analysts, reinforces the importance of monitoring volatility when constructing trades.
The research also highlights that when 1-month implied volatility falls below 40%, it is generally more favorable to buy options, either calls or puts. 
Conversely, when volatility exceeds 60%, selling options becomes more attractive.
"In the current environment, selling puts or calls around the 80% and 120% strike levels has proven relatively low-risk and potentially income-generating," the analysts wrote, noting that since January 2024, Bitcoin has only moved outside the ±20% range on two occasions out of sixteen.
10x Research contrasts the current cycle with previous ones, emphasizing that the key driver this time is not retail euphoria or halving supply shocks, but rather structured accumulation by existing holders and institutions. This includes long/short positions and arbitrage opportunities like shorting Ethereum perpetuals against Bitcoin or exploiting funding rate dislocations.
What&#8217;s Next: The decline in new Bitcoin addresses further supports the observation that new retail inflows are not driving the market.
"Capturing periodic upside moves now requires more active, tactical approaches rather than passively holding spot exposure," the report stated.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44869153/unrealized-bitcoin-losses-hit-all-time-high-glassnode-says-bear-market-signs">Unrealized Bitcoin Losses Hit All-Time High, Glassnode Says: Bear Market Signs?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

How Traders Can Make Money When Bitcoin Trades Sideways: 10x Research

The S&amp;P 500 index could still be hovering in the bubble territory as the cyclical adjusted price-to-earnings ratio, or the S&amp;P 500 Shiller CAPE ratio, remains above the level of 30 for 18 consecutive months, underscoring a rare historical trend.
What Happened: Unlike the trailing P/E, the Shiller P/E is a valuation methodology that uses a 10-year inflation-adjusted average EPS, smoothing out the impact of short-term shocks and recessions on valuation.
According to an X post by Katusa Research, the market is &#8220;approaching bubble territory,&#8221; as this metric was nearly twice its historical average of 17.58.
&#8220;By this measure (recent correction included), stocks are still historically expensive,&#8221; the post stated.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Shiller CAPE: Approaching Bubble Territory The Cyclically Adjusted Price-to-Earnings ratio (made by Robert Shiller) smooths out short-term earnings fluctuations By using 10 years of inflation-adjusted earnings. The current CAPE ratio stands at 34.97, more than double its… <a href="https://t.co/qgmkFxkP09">pic.twitter.com/qgmkFxkP09</a>
&mdash; Katusa Research (@KatusaResearch) <a href="https://twitter.com/KatusaResearch/status/1912948966070894869?ref_src=twsrc%5Etfw">April 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to the data by YCharts, the CAPE ratio was above the level of 30 for the 17th consecutive month in March and hovered at approximately 33.12 for April as of Thursday&#8217;s close.
According to a report by Motley Fool, over the last 154 years, the CAPE ratio has surpassed the level of 30 for two consecutive months, <a href="https://www.fool.com/investing/2024/12/15/stock-market-threshold-6-times-1871-history-says/?utm_source=nasdaq&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=f28929f2-4dcd-438a-8500-696d9ca0cb67">only six times</a>. 
Moreover, the S&amp;P 500 index formed a <a href="https://www.benzinga.com/25/04/44805223/the-sp-500-closes-with-first-death-cross-since-2022-heres-what-it-means-for-the-markets">death cross</a> for the first time since March 2022 last week. According to i3 Invest CEO, Guilherme Tavares, the death cross, combined with an elevated CAPE ratio, has been historically observed only three times before April 2025. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">That&#39;s it folks. The S&amp;P 500 has just triggered a death cross for the first time following a CAPE ratio that exceeded two standard deviations above its long-term exponential trend. The other 3 times this happened: &#8211; Nov/1929 &#8211; Oct/2000 &#8211; Mar/2022 Place your bets. <a href="https://t.co/hoUdiAcOIx">pic.twitter.com/hoUdiAcOIx</a>
&mdash; Guilherme Tavares (@i3_invest) <a href="https://twitter.com/i3_invest/status/1912959249065611663?ref_src=twsrc%5Etfw">April 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/25/04/44891949/chinese-commerce-ministry-pledges-retaliation-against-countries-isolating-beijing-with-us-at-the-expense-of-chinas-interests">Xi Jinping&#8217;s China Pledges Retaliation Against Countries Isolating Beijing By Giving Into Trump Administration&#8217;s &#8216;Unilateral Bullying,&#8217; Says It Will &#8216;Never Accept It&#8217;</a>
Why It Matters: The selloff is triggered by President Donald Trump&#8216;s tariffs, which have created uncertainty among investors and businesses worldwide.
While <a href="https://www.benzinga.com/25/04/44891949/chinese-commerce-ministry-pledges-retaliation-against-countries-isolating-beijing-with-us-at-the-expense-of-chinas-interests">China has been central</a> in the tariff imposition and retaliation, the administration halted the tariffs on other countries for 90 days on April 9. However, the sector-specific tariffs continue to keep the stocks on edge.
As of Thursday&#8217;s close, the S&amp;P 500 index was down 14.1% from its all-time high of 6,147.43 points. The Dow Jones Industrial Average was 13.15% below its 52-week high, whereas the Nasdaq 100 index was 17.84% lower than its previous record.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Monday. The SPY was down 0.99% to $521.20, while the QQQ declined 1.08% to $439.26, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44892375/dean-of-valuation-aswath-damodaran-warns-buying-the-dip-akin-to-catching-a-falling-">Dean Of Valuation Aswath Damodaran Warns Buying The Dip Akin To Catching A Falling Knife, Says It Takes A &#8216;Stronger Stomach&#8217; Than Most Have</a></li>
</ul>
Image Via Shutterstock

Analyst Color

Equities

Markets

General

S&P 500 'Approaching Bubble Territory:' US Stocks Remain Historically Overvalued Despite Recent Correction, Says Market Researcher

Jefferies analyst John Aiken downgrades Canadian Imperial Bank (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CM#TSX">CM</a>) from Buy to Hold and lowers the price target from C$100 to C$89.

Downgrades

TSX:CM

Jefferies Downgrades Canadian Imperial Bank to Hold, Lowers Price Target to C$89

TCBI

Axxess And Texas Capital Unveil Integration To Speed Up Payer Remittance For Care At Home Providers

In a historic first, humanoid robots ran alongside human participants in a half-marathon in Beijing, showcasing both the advancements and ongoing challenges within the robotics industry.
What Happened: The 2025 Beijing E-Town Humanoid Robot Half Marathon, held on Saturday, featured over 12,000 human participants and 21 humanoid robots, according <a href="https://www.businessinsider.com/photos-humanoid-robots-half-marathon-beijing-china-2025-4">to</a> Business Insider. 
The robots, each with a unique design, ran in a separate lane from the human runners.
The robots had approximately three and a half hours to finish the course, with awards in three categories: race completion, best endurance, and most popular robot.
Despite rigorous preparation, not all robots were able to finish the race. Some tripped and fell, while others veered off course.
See Also:&nbsp;<a href="https://benzinga.com/markets/25/04/44892201/2025-largely-doesnt-matter-for-tesla-says-gene-munster-elon-musk-company-poised-for-a-major-rebound-in-20" target="_blank" rel="noreferrer noopener">2025 &#8216;Largely Doesn&#8217;t Matter&#8217; For Tesla, Says Gene Munster: Elon Musk Company Poised &#8216;For A Major Rebound In 2026 And Beyond&#8217;</a>
Nevertheless, Tien Kung Ultra, a robot designed by the&nbsp;Beijing Humanoid Robot Innovation Center,&nbsp;made history by becoming&nbsp;the first humanoid robot to&nbsp;complete the race&nbsp;in 2 hours and 40&nbsp;minutes.
Li Quan, deputy head of&nbsp;the Beijing Economic-Technological Development Area,&nbsp;stated that the event could &#8220;spark discussions and deepen the&nbsp;public&#8217;s understanding of robot capabilities,&#8221; thereby propelling the industry&#8217;s growth.
Why It Matters: This <a href="https://www.benzinga.com/content/44716190/not-just-a-sporting-event-but-also-a-technological-test-insights-into-the-worlds-first-human-robot-c">event is not just a sporting spectacle</a> but also a technological test. The race comes at a time when tech giants like&nbsp;Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and&nbsp;Meta Platforms Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) are reportedly vying to <a href="https://www.benzinga.com/tech/25/02/43759759/apple-and-meta-in-race-to-develop-ai-powered-humanoid-robots">develop AI-powered humanoid robots.</a>
Moreover, Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) CEO Marc Benioff has expressed his belief in <a href="https://www.benzinga.com/news/25/03/44517394/the-future-of-cheap-scalable-digital-labor-marc-benioff-shares-video-of-a-chinese-robot-doing-kung-fu-that-costs-less-than-a-macbook">AI-powered agents and humanoid robots</a> as the future of digital labor. This marathon serves as a real-world demonstration of the potential and limitations of these technologies. Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://benzinga.com/news/25/04/44885628/mark-cuban-says-health-insurance-shouldnt-exist-you-dont-have-to-grab-every-nickel-when-its-the-health-of-th" target="_blank" rel="noreferrer noopener">Mark Cuban Says Health Insurance Shouldn&#8217;t Exist — &#8216;You Don&#8217;t Have to Grab Every Nickel When It&#8217;s the Health of the Entire Country at Stake&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

AAPL

Humanoid Robots Make History In Beijing Half-Marathon, Completes Race In Under 3 Hours

Axxess, the leading global technology platform for healthcare at home, and Texas Capital, a full-service financial services firm that delivers customized solutions to businesses, entrepreneurs and individual customers, announced a product integration that will enable faster payment reconciliation for home health and hospice providers. The integration between Texas Capital's RevNow product and Axxess RCM optimizes the back-office payer reconciliation workflow using sophisticated automation that matches payments and remittances, eliminating the need for manually tracking payments.

Axxess and Texas Capital Launch Automation to Simplify Payment Tracking for Healthcare Providers

"Being recognized as a Transparency Project by the White House underscores the immense strategic value of the Stibnite Gold Project," said Jon Cherry, President and CEO of Perpetua Resources. "We are honored by this selection, which validates the urgency and importance of our Project for America's economic and national security. We stand ready to restore the site and bolster American mineral independence."

PPTA

Perpetua Resources' Stibnite Gold Project Named White House Priority For Strengthening U.S. Mineral Independence

The ONE by ONE Recycling program has collected over 101 million used contact lenses, blister packs and top foils since the program's launch in November 2016. The Biotrue Eye Care Recycling program, which launched in April 2021, has collected over 1.3 million eye drop single dose units, lens cases and lens solution caps, as well as all Biotrue-branded eye drop bottles2. Bausch + Lomb has a similar contact lens recycling program in Canada called Every Contact Counts.

BLCO

Bausch + Lomb's ONE By ONE And Biotrue Eye Care Recycling Programs Collect Over 100M Units Of Used Materials

Janney Montgomery Scott analyst Timothy Coffey upgrades Banner (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANR#NASDAQ">BANR</a>) from Neutral to Buy.

Upgrades

BANR

Janney Montgomery Scott Upgrades Banner to Buy

<ul>
<li>AMG to acquire a minority equity interest in Verition, a global multi-strategy investment firm with $12.6 billion in AUM</li>
<li>Verition's management will retain a substantial majority of the firm's equity and continue to lead Verition as an independent firm, in line with AMG's partnership approach</li>
<li>Partnership further diversifies AMG's business and increases its exposure to alternative strategies</li>
</ul>

AMG Acquires Minority Stake In Verition Fund Management, Expanding Alternative Investment Strategies

Creating symmetrical, same-size gold nanospheres in microgravity that could accelerate speed and accuracy of blood tests for cancer, other diseases

Redwire Expands Drug Development In Microgravity With PIL-BOX And New Cancer-Detection Experiment On ISS

Health Care

CTSO

CytoSorbents Received $1.7M In Cash Proceeds From The Sale Of Its 2023 And Amended 2022 Net Operating Loss And R&D Tax Credits From The Technology Business Tax Certificate Transfer Program, Sponsored By The New Jersey Economic Development Authority

MLEC

Moolec Science Sa Announced That It Has Entered Into A Business Combination Agreement With Bioceres Group Limited and Other Related Entities In An All-stock Transaction

Earnings

Earnings Beats

HBT Finl Q1 2025 Adj. EPS $0.61 Beats $0.57 Estimate, Sales $58.014M Beat $57.380M Estimate

Press Releases

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Jasper Therapeutics to Present at Upcoming March Investor Conferences

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Comments

Jasper Therapeutics

Jasper Therapeutics (JSPR) Opciones

Jasper Therapeutics (NASDAQ:JSPR) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL